“十四五”天津高新区生物医药产业“量质齐升”

Core Insights - The Binhai High-tech Zone in Tianjin has positioned the biopharmaceutical industry as a core leading industry during the 14th Five-Year Plan, achieving an average annual growth rate of 16% in output value and maintaining a top ranking among national biopharmaceutical industrial parks for three consecutive years [1][2]. Group 1: Development Achievements - The high-tech zone has established nearly 20 national-level innovation platforms and over 60 municipal-level innovation platforms in the biopharmaceutical field, contributing to nearly 30 national and Tianjin municipal science awards [2]. - A comprehensive industrial chain has been formed in the cell and gene therapy sector, encompassing cell extraction and preparation, storage, cold chain logistics, innovative research and development, pilot testing, regulatory approval, and clinical application, with over 100 upstream and downstream enterprises [2]. Group 2: Future Outlook - Looking ahead to the 15th Five-Year Plan, the high-tech zone aims to become a national leader in biotechnological and biomanufacturing industries, focusing on five core sectors: innovative drugs, medical devices, cell therapy, brain-computer interaction, and pharmaceutical services [3]. - The development strategy includes strengthening the "Cell Valley" and "China Brain-Computer Valley" as key innovation and industrial hubs, while also exploring potential industries such as biomanufacturing, healthcare, and wellness [3].